Key points are not available for this paper at this time.
Neoadjuvant chemotherapy with epirubicin plus docetaxel was a feasible treatment and was active in an unfavorable series of patients with locally advanced breast carcinoma, including patients with inflammatory breast carcinoma.
Matteis et al. (Fri,) studied this question.